We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cytokinetics Inc | NASDAQ:CYTK | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.25 | -1.92% | 64.02 | 63.50 | 78.10 | 68.44 | 61.75 | 68.21 | 2,404,751 | 01:00:00 |
From Nov 2023 to May 2024
By Ben Glickman
Shares of Cytokinetics jumped Monday after the Wall Street Journal reported the company was close to being bought by Novartis.
The stock was up 16% to $109.22 after the news broke, reversing declines earlier in the day. Shares have more than doubled in the last year.
A deal could be finalized as soon as this week, people familiar with the situation told WSJ. Cytokinetics has been running a sale process and another buyer could potentially emerge.
Novartis shares were down 0.4% to $105.90.
Cytokinetics shares surged last month after releasing positive data for a potential treatment for hypertrophic cardiomyopathy, a genetic heart condition.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 13:28 ET (18:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Cytokinetics Chart |
1 Month Cytokinetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
